Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult: a case report

Dell’Unto, Elisabetta; Rinzivillo, Maria; Esposito, Gianluca; Iannicelli, Elsa; Prosperi, Daniela; Panzuto, Francesco; Annibale, Bruno

doi:10.1093/gastro/goae023

Gastroenterology Report

2023

DOI: 10.1093/gastro/goae023

|View full text |Cite

Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult: a case report

Elisabetta Dell’Unto,

Maria Rinzivillo,

Gianluca Esposito

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Gastric neuroendocrine tumors: 20‐Year experience in a reference center

Ravizza,

Giunta,

Sala

et al. 2024

J Neuroendocrinology

View full text Add to dashboard Cite

Few studies have been published on the long‐term outcomes of patients with gastric neuroendocrine tumors (gNETs). We analyzed their management over a two‐decade period, focusing on endoscopic and clinical outcomes. Clinical, laboratory, endoscopic, surgical, and histopathological data from Types 1 and 3 gNETs histologically diagnosed between March 2000 and December 2021 at the European Institute of Oncology (IEO, Milan) were retrospectively collected. Sixty‐nine patients were included (60 Type 1, 9 Type 3): 53 (77%) were treated endoscopically, 6 (9%) surgically, and 10 (14%) did not receive any treatment. Overall, 293 lesions were removed endoscopically: 74% by forceps, 20% by endoscopic mucosal resection (EMR), and 5% by endoscopic submucosal dissection (ESD). No differences were observed between EMR and ESD in terms of complete resection rate (p value = .50) and complications rate (p value = .084). The median follow‐up period was 5.8 years (range: 0.3–20.5), during which no gNET‐related deaths were observed. Metachronous gNETs developed in 60% of patients with Type 1 gNET. Six patients with lymph node metastases (LNM) were younger (p value = .006) and had larger lesions (p value <.001) than patients without LNM. Most Type 1 gNETs were successfully excised using forceps, with EMR and ESD being equally effective. The presence of incomplete resection was not associated with a worse prognosis, which remains excellent in this highly recurrent disease. Younger age and a size ≥10 mm were associated with an increased risk of LNM.Clinical Trial RegistrationProject code UID 2854.

show abstract

Gastric neuroendocrine tumors: 20‐Year experience in a reference center

Ravizza,

Giunta,

Sala

et al. 2024

J Neuroendocrinology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult: a case report

Cited by 1 publication

References 10 publications

Gastric neuroendocrine tumors: 20‐Year experience in a reference center

Gastric neuroendocrine tumors: 20‐Year experience in a reference center

Contact Info

Product

Resources

About